Skip to main content

Suzanne Bruhn

Equibles does not estimate personal net worth.

Get an email with a short summary when Definium Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get DFTX alerts

About Suzanne Bruhn

Suzanne Bruhn is recorded as Board Member at Definium Therapeutics, Inc. (DFTX) since June 12, 2025. Definium Therapeutics, Inc. reported in an 8-K filed June 12, 2026 that Suzanne Bruhn was appointed Director, effective June 11, 2026. Definium Therapeutics, Inc. reported in an 8-K filed June 16, 2025 that Suzanne Bruhn was appointed member of the Board, effective June 12, 2025. Definium Therapeutics, Inc. reported in an 8-K filed August 11, 2022 that Suzanne Bruhn was appointed Director, effective August 11, 2022. Definium Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Definium Therapeutics, Inc. includes Dr. Roger Crystal (CEO), Dr. Suzanne Bruhn (CEO), JR Rahn (CEO) and 7 others.

“The Company's seven nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett, were each elected to serve as a member of the Board until the 2027 annual general meeting of shareholders (the "2027 Annual Meeting") or until a successor has been duly elected or appointed, by the following votes:”
Definium Therapeutics, Inc. Form 8-K, filed June 12, 2026 · Read the filing
“The Company's six nominees, Robert Barrow, Dr. Suzanne Bruhn, Dr. Roger Crystal, David Gryska, Andreas Krebs, and Carol A. Vallone, were each elected to serve as a member of the Board until the 2026 annual general meeting of shareholders (the "2026 Annual Meeting") and until his or her successor is duly elected or qualified, by the following votes:”
Definium Therapeutics, Inc. Form 8-K, filed June 16, 2025 · Read the filing

Affiliation history

Company network

Leadership on record at Definium Therapeutics, Inc.

Recent activity